Russell D Petty

List of Publications by Year in descending order

41	1,794	516710	315739
papers	citations	16	38
		h-index	g-index

44	44	44	3025
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncology, The, 2014, 15, 894-904.	10.7	270
2	Comparison of MTT and ATP‐based assays for the measurement of viable cell number. Luminescence, 1995, 10, 29-34.	0.0	201
3	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 420-435.	10.7	191
4	Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nature Genetics, 2012, 44, 1131-1136.	21.4	162
5	A Deep Learning Framework for Predicting Response to Therapy in Cancer. Cell Reports, 2019, 29, 3367-3373.e4.	6.4	137
6	Gene Expression Profiling in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 3237-3248.	7.0	131
7	Gefitinib and <i>EGFR</i> Gene Copy Number Aberrations in Esophageal Cancer. Journal of Clinical Oncology, 2017, 35, 2279-2287.	1.6	100
8	Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer. JAMA Oncology, 2021, 7, 869.	7.1	83
9	Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. , 2019, 203, 107395.		76
10	Tumor Transcriptome Reveals the Predictive and Prognostic Impact of Lysosomal Protease Inhibitors in Non‐Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 1729-1744.	1.6	61
11	Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.. Journal of Clinical Oncology, 2019, 37, 4006-4006.	1.6	49
12	Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 854-862.	8.1	47
13	Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer, 2015, 15, 762.	2.6	38
14	Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers. British Journal of Cancer, 2021, 125, 1068-1079.	6.4	23
15	Predicting Response to Treatment in Gastroesophageal Junction Adenocarcinomas: Combining Clinical, Imaging, and Molecular Biomarkers. Oncologist, 2010, 15, 270-284.	3.7	22
16	The impact of COVID-19 on systemic anticancer treatment delivery in Scotland. British Journal of Cancer, 2021, 124, 1353-1356.	6.4	22
17	Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose. Journal of Gastrointestinal Cancer, 2012, 43, 168-176.	1.3	21
18	Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2. Computational and Structural Biotechnology Journal, 2022, 20, 2091-2111.	4.1	18

#	ARTICLE	IF	CITATIONS
19	Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial). Cancer Chemotherapy and Pharmacology, 2016, 77, 819-827.	2.3	14
20	Novel biomarkers for risk stratification of Barrett's oesophagus associated neoplastic progression–epithelial HMGB1 expression and stromal lymphocytic phenotype. British Journal of Cancer, 2020, 122, 545-554.	6.4	14
21	Optimized EGFR Blockade Strategies in *EGFR* Addicted Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 3126-3140.	7.0	11
22	Serpin B3 Is Associated with Poor Survival after Chemotherapy and Is a Potential Novel Predictive Biomarker in Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1502-1509.	1.1	9
23	A modified Delphi process to establish future research priorities in malignant oesophagogastric surgery. Journal of the Royal College of Surgeons of Edinburgh, 2020, 18, 321-326.	1.8	9
24	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience. Journal of Clinical Oncology, 2022, 40, 2458-2467.	1.6	9
25	Bone metastasis from epithelial ovarian carcinoma. Lancet Oncology, The, 2002, 3, 513.	10.7	8
26	Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma. Molecular Cytogenetics, 2015, 8, 78.	0.9	8
27	Novel Fluoropyrimidines: Improving the Efficacy and Tolerability of Cytotoxic Therapy. Current Cancer Drug Targets, 2004, 4, 191-204.	1.6	8
28	Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the GO2 trial. Journal of Geriatric Oncology, 2022, 13, 287-293.	1.0	8
29	Real-world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review). International Journal of Oncology, 2021, 58, .	3.3	7
30	Biomarkers and novel agents in esophago-gastric cancer: are we making progress?. Expert Review of Anticancer Therapy, 2015, 15, 1103-1119.	2.4	6
31	Best supportive care and prognosis: advanced gastroesophageal adenocarcinoma. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2020-002637.	1.6	6
32	Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma. Lancet, The, 2018, 392, 97-98.	13.7	5
33	Exclusive rights in gastric cancer genomics: Figure 1. Gut, 2012, 61, 638-640.	12.1	4
34	Why is renal impairment associated with poorer cancer specific survival in breast cancer patients?: a comparison with patients with other comorbidities. International Journal of Clinical Oncology, 2020, 25, 1786-1792.	2.2	3
35	Cardiotoxicity and Chemotherapy—The Role of Precision Medicine. Diseases (Basel, Switzerland), 2021, 9, 90.	2.5	3
36	Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma. British Journal of Cancer, 2020, 123, 1585-1587.	6.4	2

#	Article	IF	Citations
37	Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed. Cancer Chemotherapy and Pharmacology, 2021, 87, 361-377.	2.3	2
38	Prognostic RNAs in oesophageal squamous cell carcinoma: small is beautiful. Gut, 2017, 66, 210-211.	12.1	1
39	Cancer Treatment Helpline: a retrospective study of the NHS Tayside experience. BMJ Open Quality, 2021, 10, e001488.	1.1	1
40	Identification of coronavirus particles by electron microscopy: a complementary tool for deciphering COVID-19. European Respiratory Journal, 2022, , 2200754.	6.7	1
41	Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the young international society of geriatric oncology. Journal of Geriatric Oncology, 2021, , .	1.0	0